NSE-listed pharmaceutical companies offering contract development and manufacturing (CDMO) services for APIs, intermediates, and drug products — India's growing role as the world's pharmacy of choice.
Sectors represented: Healthcare
RapidmomentuminspecializedCDMOservicestosupportever. increasingclinicaltrials,e.g.,HighpotencyAPIswithstringent. exposurecontrolrequirements. . Risingshareofbiologicsalongwithincreasinginvestmentsin. biologicsfornewnichemodalities CDMOservicestosupportever. increasingclinicaltrials,e.g.,HighpotencyAPIswithstringent. exposurecontrolrequirements. .
Our comprehensive and. customized services for Drug Substances (DS) and Drug. Products (DP) offer innovative solutions to ensure timely. and safe drug development. rs at every. stage of drug development. Our comprehensive and. customized services for Drug Substances (DS) and Drug. Products (DP) offer innovative solutions to ensure timely. and safe drug development. We conduct custom synthesis.
Robust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business. 17 obust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business...
The global pharmaceutical contract development and manufacturing. organisation (CDMO) market is experiencing significant growth, valued. at US$166.0 Billion in 2025 and projected to reach US$293.6 Billion global pharmaceutical contract development and manufacturing. organisation (CDMO) market is experiencing significant growth, valued.
DCGI approvals. 1. , along with. 923 FSSAI approvals. 150. 4. 925+. 3. (1) As of 31st March 2024; (2) As of 1st Aug 2024. Domestic Branded Formulations. 59. th. Rank in Indian Branded. Formulations. 1. 140. Brands. 69%. Chronic and. sub-chronic segment. 1. 1.5k+. Salesforce. Exports Oriented Branded Formulations. 179. 246. 134. 289. Mar’22Mar’23Mar’24. Under Registration. Dossiers.
CDMO / CMO. 8. ❏Sustainable supply for APIs/NCEs/Intermediates in commercial scale. ❏Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS). ❏EHS and Quality are the highest priority. nue. CDMO / CMO. 8. ❏Sustainable supply for APIs/NCEs/Intermediates in commercial scale. ❏Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS).
Our Quality Control laboratories are. equipped with advanced analytical instruments. such as LCMS, GCMS, ICP-MS and XRD, enabling. precise characterisation and release testing of. drug substances in accordance with global l laboratories are. equipped with advanced analytical instruments. such as LCMS, GCMS, ICP-MS and XRD, enabling. precise characterisation and release testing of.
This shift is further reinforced by transitioning to. an asset-light model, which reduces operating and capital. expenditures. locate resources. more effectively toward innovation and commercial. growth. This shift is further reinforced by transitioning to. an asset-light model, which reduces operating and capital. expenditures. By leveraging CDMOs' streamlined procedures.
Contract Research Development and Manufacturing Organizations (CRDMO). One-stop service solution is a business model of pharmaceutical contract organizations that provides services. covering entire value chain. 1. 1. 1. 2 h Development and Manufacturing Organizations (CRDMO). One-stop service solution is a business model of pharmaceutical contract organizations that provides services.
Drug Product (Formulation)Drug Substance (API)Total. 92. 95. 106. 113. 120. 129. 139. 150. 162. 176. 190. 2019202020212022202320242025F2026F2027F2028F2029F. 3.1. 3.4. 3.8. 4.3. 5.0. 5.6. 6.2. 7.1. 8.2. 9.5. 10.8 920242029F. Drug Product (Formulation)Drug Substance (API)Total. 92. 95. 106. 113. 120. 129. 139. 150. 162. 176. 190. 2019202020212022202320242025F2026F2027F2028F2029F. 3.1. 3.4. 3.8. 4.3.
Contract Development and Manufacturing Organization. (CDMO). CDMO Market. The global CDMO market (small + large molecules) was valued at USD ~130 ch. partner rather than a transactional service provider. Contract Development and Manufacturing Organization. (CDMO). CDMO Market. The global CDMO market (small + large molecules) was valued at USD ~130.
High-Potency APIs (HPAPIs). HPAPIs represent one of the most technically. demanding API segments. edibility a key. differentiator influencing supplier selection and. contract longevity. . High-Potency APIs (HPAPIs). HPAPIs represent one of the most technically. demanding API segments. The HPAPI market is. projected to grow from ~USD 30 billion in 2025 to. ~USD 48.3 billion by 2033. [6].. .
APIs with low competitive intensity. Ongoing augmentation of new. product pipeline. Built deep cost position through. backward integration. Top 3 player in 8 out of 10 top. molecules in the API portfolio. Formulation: : Offering end to end. vertically integrated solutions. including pellets and formulations. for partners. We have more nearly 50 product. families in the APIs and formulation.
Process DevelopmentQuality & Regulatory ServicesDrug Substance Drug Product. . Mammalian and microbial platforms. . Single-use bioreactors for lower cost, reduced. contamination risk and higher uptime. . Clinical batches to high-speed commercial. lines inc. ug Substance Drug Product. . Mammalian and microbial platforms. . Single-use bioreactors for lower cost, reduced.